PODD— AI Stock Forecast & Price Targets
Published 8/5/2026 · A free sample of K3vl4r’s AI-powered analysis.
Kronos price forecasts, scored fundamentals & technicals, and a multi-horizon plan.
View the live PODD price forecast →
PODD's Q2 print delivered a headline beat ($801.7M rev +23.5% YoY, non-GAAP EPS $1.66 vs $1.45 est) but soft Q3 revenue guide ($833.4M, ~1.6% below consensus) triggered a violent -12.79% gap down to ~$148, breaking the $160 support that has anchored this range for weeks. Elite unit economics (71% GM, 23% ROE) and now-cheaper 18x forward multiple are intact, but the tape has spoken — momentum thesis is broken and we treat this as a HOLD with a willingness to accumulate lower as the dust settles.
1-4 weeks: HOLD; do NOT chase into today's collapse and do NOT catch a knife. The earnings binary has now resolved bearishly — allow 2-3 sessions for forced selling / index rebalancing to work through. Watch for a reclaim of $155 on above-average volume as the first sign of stabilization; a failure to hold $145 opens the $138.79 52w low retest. If shorted or hedged into the print you keep the hedge with a stop at $158; if unhedged long, tighten stop below $138. Do not initiate new longs above $155 until a base forms.
1-6 months: cautious ACCUMULATE on weakness rather than at these levels. The franchise is genuinely cheaper (~18x fwd, PEG <1) with elite margins intact, and the Omnipod 5 enhanced algorithm rollout, Libre 3 Plus compatibility, and Evolve Type 2 pipeline all remain live catalysts. A staged entry — one tranche at $142-$145 (near 52w low retest), a second at $132-$135 if it breaks — targets a gap-fill toward $170 base and $200 bull case over 6 months once the class action / recall overhang crystallizes. What would change my mind negatively: additional recall expansion, an FDA warning letter, or FY26 CER guide cut below 20%; positively: sustained volume-backed reclaim of $160 with the class action settled/discounted.
1-3 years: the structural bull case is intact — Omnipod is the leading tubeless AID platform, ~25% YoY customer growth, international expansion accelerating, EVOLUTION T1D and Evolve Type 2 both extending TAM meaningfully with commercial launch targeted 2028, and 5Y EPS CAGR estimated ~27%. On $8.05 forward EPS growing mid-20s%, a normalization to 28-32x forward yields $225-$260 in 2-3 years. The biggest structural risks are (1) GLP-1 secular compression of the Type-2 insulin-dependent TAM, (2) commoditization of closed-loop algorithms as Medtronic/Tandem/Beta Bionics converge, and (3) single-CGM-partner dependence on Dexcom/Abbott. Product concentration in the Omnipod family remains the biggest single-point-of-failure risk.
The just-reported Q2 quantifies what the franchise looks like operationally: revenue of $801.7M was +23.5% YoY and above the $761.7M Q1 pace, GAAP EPS $1.37 up 328% YoY, and non-GAAP EPS $1.66 beat by 14.3% — this is not a broken business. Trailing gross margin sits at 71%, operating margin 16-17%, ROE 23%, ROIC 13.6%, and TTM sales growth ~32% — top-decile medtech quality. The balance sheet remains sound (cash $480M, total debt $948M, current ratio 2.49), though the cumulative $640M cash decline from Jun-25 ($1.12B) to Mar-26 ($480M) and the Q4 2025 $149M capex spike remain the two line items I most want management to walk through on the call; heavy capacity build is consistent with the FY26 guide but pressures near-term FCF (Q1 FCF $86M vs. $173M a year prior). What broke today was the forward guide, not the model: Q3 revenue guidance of $833.4M implies deceleration and was 1.6% short of expectations — enough to break the multiple-expansion trade. On $8.05 forward EPS at $148, the stock is now ~18.4x forward and PEG well under 1, which is objectively cheaper than at any point this year.
The 1h chart shows the setup clearly: PODD ran to ~$173 pre-print then vertically collapsed to $148 on the release, a single-bar violation of the $155-$160 base that had held all of July. On the daily, price has now given up the entire July recovery and sits just ~$9 above the 52-week low of $138.79 and roughly -28% below the SMA200. The weekly shows we are at multi-year lows in a name that traded $340+ nine months ago — a completed capitulation pattern is possible here but not confirmed. RSI at ~55 pre-print will reset lower; expect an oversold bounce but structural resistance now stacks at $160 (former support becomes resistance), then the $167-$170 gap-fill zone, then the tested $180 cap. Downside supports are $145 (today's low area), $138.79 (52w low), and psychological $135. The AI forecast bands calling for $240-$260 look aspirational against realized accuracy that beats naive baseline by only 2 points on 1d and is BEATEN by naive on 1wk — I discount them heavily and anchor to price action.
The Q2 print is the only thing that matters today: revenue and EPS both beat, but the Q3 guide miss (~1.6% light) explains the -12.79% reaction — the market is repricing growth deceleration and lingering recall/quality overhang, not the current quarter. Secondary signal-worthy items: the Calm partnership (July 14) is a soft ecosystem/brand play, not a P&L mover; the BGM market growth report (8.9% CAGR to 2035) confirms the secular tailwind is real; the ChartMill 'Affordable Growth' framing lines up with a PEG of 0.78 and now looks more valid after today's markdown. The live overhangs — the federal securities class action (Aug 31 lead-plaintiff deadline) alleging misleading safety claims on Omnipod manufacturing, plus the FDA-acknowledged pod removal letter — are unresolved and got fresh oxygen from today's tape. UBS's late-July Neutral downgrade on valuation now looks prescient. Congressional STOCK Act shows a Senator's spouse trimmed a $100-250k position twice in late April/early May — a slow negative positioning signal that we now know front-ran a rough print. Retail sentiment on stocktwits is 100% bullish which, on a name that just gapped -12.79%, is a mild contrarian caution flag.
- Omnipod 5 enhanced algorithm with 100 mg/dL target and Abbott Libre 3 Plus sensor compatibility rolling out US H1 2026 / Int'l H2 2026, deepening ecosystem lock-in
- Evolve Type 2 pivotal study underway in 2026, 510(k) filing targeted 2027, commercial launch 2028 — meaningful TAM expansion beyond Type 1
- EVOLUTION T1D trial seeding next-generation AID platform / future Omnipod 6 upgrade cycle
- International customer growth compounding at ~45%+ pace off a smaller base with Asian market entry optionality
- Global customer base grew ~25% YoY in Q1 2026 — recurring pod consumables drive durable revenue runway
- Q2 non-GAAP EPS $1.66 (+14% beat) validates operating leverage — margin trajectory intact even with capex build
- Q3 revenue guidance $833.4M came in ~1.6% below consensus, triggering today's -12.79% gap — the market is now pricing growth deceleration
- Active federal securities class action alleging misleading Omnipod manufacturing/safety claims; Aug 31 lead-plaintiff deadline keeps overhang alive
- FDA-acknowledged pod removal letter and unquantified 'correction costs' related to quality issues remain a P&L wildcard
- $640M cumulative cash decline (Jun 2025 → Mar 2026) and Q4 2025 $149M capex spike still weigh on FCF; Q1 FCF halved YoY to $86M
- GLP-1 adoption compressing the Type-2 insulin-dependent TAM long-term; single-CGM-partner dependence on Dexcom/Abbott is a single point of failure
- Intensifying competition from Tandem/Medtronic/Beta Bionics on closed-loop algorithms threatens differentiation
- Technical damage — break of $160 range floor and price sitting ~$9 above 52w low with SMA200 -28% overhead
- Product concentration: essentially a single-platform franchise (Omnipod), any manufacturing setback disproportionately hits results
Get AI analysis on any stock
This is one of hundreds of Kronos AI reports — scored fundamentals & technicals, bull/base/bear price targets, a multi-horizon plan, and continuously-updated forecasts across the market. Create a free account to explore them all.
Create your free account →Already a member? Sign in · Join our Discord